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The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new
evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the
axilla and shorter durations of radiation therapy. It reﬁned its earlier approach to the classiﬁcation and management of
luminal disease in the absence of ampliﬁcation or overexpression of the Human Epidermal growth factor Receptor 2
(HER2) oncogene, while retaining essentially unchanged recommendations for the systemic adjuvant therapy of HER2-
positive and ‘triple-negative’ disease. The Panel again accepted that conventional clinico-pathological factors provided a
surrogate subtype classiﬁcation, while noting that in those areas of the world where multi-gene molecular assays are
readily available many clinicians prefer to base chemotherapy decisions for patients with luminal disease on these
genomic results rather than the surrogate subtype deﬁnitions. Several multi-gene molecular assays were recognized as
providing accurate and reproducible prognostic information, and in some cases prediction of response to chemotherapy.
Cost and availability preclude their application in many environments at the present time. Broad treatment
recommendations are presented. Such recommendations do not imply that each Panel member agrees: indeed, among
more than 100 questions, only one (trastuzumab duration) commanded 100% agreement. The various recommendations
in fact carried differing degrees of support, as reﬂected in the nuanced wording of the text below and in the votes
recorded in supplementary Appendix S1, available at Annals of Oncology online. Detailed decisions on treatment will as
always involve clinical consideration of disease extent, host factors, patient preferences and social and economic
constraints.
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introduction
The 2 years since the 2011 St Gallen Consensus [1] have seen
substantial progress in evidence relevant to various aspects of
the treatment of early invasive breast cancer. The genomic atlas
of the disease [2] has emphasized its heterogeneity, and
suggested that genomic studies may potentially inform
treatment decisions such as the use of aromatase inhibitors
[3, 4]. Further data became available reducing the necessity for
axillary dissection [5, 6]. Studies presented at the 2012 ESMO
meeting clariﬁed the optimal duration of adjuvant trastuzumab
in HER2-positive disease [7, 8]. The duration of adjuvant
tamoxifen was addressed by the ATLAS study, which suggested
a signiﬁcant beneﬁt for extending such treatment to 10 years
rather than 5 years [9].
St Gallen 2013: news and progress
The 13th International Breast Cancer Conference held in St
Gallen in March 2013 involved some 3700 participants from 95
countries and heard presentations from a faculty widely
representative of disciplines and geographical areas. An Expert†See Appendix 1 for members of the Panel.
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Panel, which included 51 members from 21 countries, chaired
by Aron Goldhirsch and Eric P. Winer met at the conclusion of
the conference to review the new information presented and
consider treatment recommendations for broad application over
the next 2 years. As in the past, this conference included an
explicit approach to management of conﬂicts of interest (see
Appendix 2).
Table 1 summarizes the information presented during the
conference.
Recent research in local therapy supports the continued trend
towards less extensive procedures. Thus, axillary dissection can
safely be omitted for patients with micrometastatic disease in
sentinel nodes [65] and for those undergoing breast-conserving
surgery and whole breast radiation therapy with up to two
macroscopically positive sentinel nodes [66] (Table 1).
Two large studies [68, 69] support the safety and efﬁcacy of
shorter courses of whole breast radiation therapy (40 Gy in 15
or 42.5 Gy in 16 fractions), which offer advantages of
convenience and cost over the previous standard of 50 Gy in 25
fractions.
New information became available for several aspects of
systemic adjuvant therapy. The ATLAS trial reported
superiority for 10 years compared with 5 years of adjuvant
tamoxifen [9]. Further follow-up of the extended adjuvant study
(MA.17) suggested particular beneﬁt of letrozole for patients
who were premenopausal at diagnosis but became
postmenopausal by the time of letrozole administration [86].
The optimal duration of trastuzumab therapy in HER2-
positive disease was clariﬁed by results from two trials. The
HERA trial [7] showed no additional beneﬁt of 2 years
trastuzumab compared with 1 year, while the PHARE trial [8]
failed to show non-inferiority of 6 months trastuzumab
compared with 1 year. Thus, the de facto standard of care
remains 1 year of trastuzumab in patients with HER2-positive
disease.
The Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) meta-analysis of trials of chemotherapy versus no
chemotherapy [18] failed to deﬁne any group for which
chemotherapy did not offer an advantage. This conclusion is at
odds with the results of individual trials and prospective/
retrospective analyses of trials with assays such as the 21-gene
recurrence score (RS). Furthermore, the control groups of trials
included in the EBCTCG overview appear to exhibit much
higher degrees of risk than that of patients with luminal disease
seen in today’s practice who receive modern endocrine therapy
as the backbone for their treatment. The EBCTCG report noted
that ‘information was lacking about tumour gene-expression
markers or quantitative immunohistochemistry that might help
to predict risk, chemosensitivity, or both’ [18]. Subsequent
editorial comments [93, 94] drew differing interpretations of the
EBCTCG conclusions.
breast cancer subtypes
The clinico-pathological surrogate deﬁnitions of subtypes as
adopted by the Panel are summarized in Table 2, and their
broad implications for systemic treatment selection are
described in Table 3.
Further evidence has accrued in the last 2 years to support the
use of multi-gene signatures to make distinctions among
patients with luminal disease. Many different multi-gene assays
provide prognostic information, primarily derived from their
sampling of proliferation genes [97], which emphasizes the need
for some measure of proliferation in any surrogate classiﬁcation.
The 21-gene RS is accepted as providing not only prognostic,
but also predictive information regarding the utility of cytotoxic
therapy in addition to endocrine therapy for patients with
luminal disease. This and perhaps other multi-gene assays can
help deﬁne a group of patients for whom chemotherapy is futile
because the biological nature of the tumour is such that it is
substantially unresponsive to such agents. Existing studies of the
21-gene RS involve retrospective analysis of previously
conducted randomized clinical trials [75, 76], which included
both HER2-positive and HER2-negative cohorts. A recent
report demonstrated excellent 5-year outcome without
chemotherapy for a ‘good prognosis’ 70-gene signature
cohort [49].
In those areas of the world where multi-gene assays are
readily available, clinical practice has developed to rely on the
results to guide decisions about inclusion of chemotherapy in
the treatment of patients with ER-positive, HER2-negative
disease. The 70-gene assay returns a dichotomous result,
while 21-gene RS is continuous. An unresolved question is
the level of RS which should justify cytotoxic therapy: only
high RS values (>31) were signiﬁcantly associated with
chemotherapy beneﬁt in the prospective/retrospective studies
[75, 76], while substantially lower values are being
investigated in ongoing prospective trials and are being used
in clinical practice. For many societies, the cost of these
multi-gene assays remains prohibitive.
The possibility that multi-gene expression assays may become
more widely available was discussed by some Panellists after the
meeting during the preparation of this manuscript. Cost-
effectiveness studies have been carried out in the United States
[98, 99], Canada [100–104], Israel [105], the UK [106] and
Germany [107, 108]. These studies have yielded varying
estimates ranging from cost-saving to an incremental cost-
effectiveness ratio (ICER) of ∼US $60 000 per quality-adjusted
life year (QALY). One Japanese study of the 70-gene assay [109]
found an ICER of US $40 000 per QALY. Such assessments will
be sensitive not only to the cost of the test, but to the net
proportion of patients in whom testing leads to the omission of
cytotoxic therapy, and to the cost of the cytotoxic regimen
which would otherwise have been given. These reports have
largely worked from the perspective of the health care system or
third-party payer, and thus offer hope that such bodies may
increasingly support multi-gene testing. It has recently been
reported that the UK National Institute for Clinical Excellence,
having reached a conﬁdential pricing arrangement with the
supplier, has issued a draft recommendation that the 21-gene
RS be used for women with node-negative disease for whom
the indication for chemotherapy is otherwise uncertain1.
Meanwhile, in many settings patients can only access multi-
gene testing by large personal out-of pocket payments, and
therefore, from a global perspective for the immediate future
1http://guidance.nice.org.uk/DT/4 accessed 3 May 2013
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Table 1. Recent research ﬁndings presented at the 13th International Conference on Primary Therapy of Early Breast Cancer and their implications for
patient care
Field or treatment Status of research/implications for patient care
Targeted treatments Proof of concept of mTOR pathway inhibition in metastatic disease was provided by the Bolero study [10]. The PI3K-alpha
inhibitors, such as GDC-0032, have shown strong interaction with ER signalling in laboratory studies. Another PI3K-
alpha inhibitor, BYL719, showed preclinical evidence of synergy with fulvestrant. The strong preclinical evidence for
favourable interaction between endocrine therapy and various inhibitors of the PI3 kinase pathway (AKT inhibitors or
MEK inhibitors) points to the need for clinical trials of such combinations [11]. In triple-negative breast cancer, PI3K
inhibition impairs BRCA1/2 expression, thus sensitizing cells to PARP inhibition [12, 13].
A frequently mutated gene is TP53, which is abnormal in the majority of cases of HER2 overexpressing and triple-negative
disease [2, 14]. Although, p53 has been studied for decades, its clinical utility remains limited due to the absence of
standardization and the heterogeneity of the studies. Wild-type p53 activity impairs the preclinical response to
anthracyclines [15], and there is an interaction with ER such that ER prevents p53-dependent apoptosis [16]. However,
p53 was not predictive of preferential sensitivity to an anthracycline-based versus a taxane-based chemotherapy in a large
phase III neoadjuvant study [17].
Messages from the EBCTCG
Overview
The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis showed efﬁcacy of adjuvant chemotherapy
compared with no chemotherapy, superiority of anthracycline-based regimens over CMF and of taxane-containing
regimens over those based on anthracycline. The relative magnitude of beneﬁt from anthracycline or anthracycline-taxane
combinations resulted in similar reductions of breast cancer mortality irrespective of age, stage, histopathological grade
and ER status, although the absolute gain for a low disease burden Luminal A-type of cancer will be very small [18, 19].
Mutational analysis of breast
cancer
Detailed analysis of the entire genome of breast cancers offers the potential for more precisely personalizing therapy [20].
Application is currently limited by the availability of suitably targeted therapeutic agents and by limited understanding of
the roles and functions of many of the identiﬁed abnormalities, and clariﬁcation of which genomic alterations are
functional and which are merely passenger mutations.
Personalizing treatment Analytic validity, clinical (or biologic) validity, and clinical utility are all required for optimal clinical application of tumour
biomarkers [21].
Intrinsic subtypes Identiﬁcation of intrinsic subtypes is most precise using molecular technologies [22]. Where such assays are unavailable,
surrogate deﬁnitions of subtype can be obtained by IHC measurements of ER, PgR, Ki-67 and HER2 with in situ
hybridization conﬁrmation, where appropriate [23]. Moderate or strong expression of PgR has been proposed as an
additional restriction in the surrogate deﬁnition of ‘Luminal A-like’ disease [24]. Ki-67 level as a marker of proliferation is
also important for this distinction [23]. Both of these markers require quality control. In particular, Ki-67 measurement is
not currently standardized among laboratories [25–27] (see panel deliberations below).
Lifestyle issues Epidemiological evidence suggests that a ‘Mediterranean’ diet is associated with a modest reduction in the risk of the
occurrence of breast cancer [28]. Several recent meta-analyses have conﬁrmed the association of physical activity with
reduced breast cancer incidence and improved prognosis [29].
Hormonal inﬂuences Sex hormones, particularly estrogens, are recognized as important in deﬁning the risk of occurrence of breast cancer, and
may be important in particular treatment situations, such as the use of aromatase inhibitors. However, analytical issues
still limit the measurement of estrogen at low but clinically relevant levels [30, 31].
Hereditary breast cancer Factors to be considered regarding recommendation for genetic testing include known mutation in the family, patient or
close relative with breast cancer diagnosis <35, patient or close relatives with ovarian or fallopian tube cancers, multiple
pancreatic cancers, and some pathological features. However, intrinsic subtype cannot safely be used to exclude the need
for genetic testing [32].
Obesity and fat Obesity is widely recognized as a risk factor for both occurrence and worsened prognosis of breast cancer [33]. Obesity is not
clearly predictive of AI (versus Tam) beneﬁt in postmenopausal women [34–36], but may be predictive of reduced AI
beneﬁt in premenopausal women [37].
Evidence exists that adipose tissue contains pluripotent stem cells, which might be responsible for tumour angiogenesis [38, 39].
Such cells have been shown to promote breast cancer growth in preclinical models [40], raising the hypothetical concern that
use of adipose tissue in breast reconstruction might increase the risk of recurrence.
Metastasis, microenvironment,
bone and bisphosphonates
Metastasis is a complex event governed by host interactions. Characteristics of the microenvironment are important in the
metastatic process. In preclinical models, tenascin C promotes the aggressiveness of metastasis [41] and autocrine tenascin
C is required for early colonization [42].
Bisphosphonates may have beneﬁcial effects in estrogen-deprived women [43–45]. This beneﬁt, which remains uncertain,
does not appear to be limited to the inhibition of bone metastases.
Metronomic chemotherapy Metronomic chemotherapy demonstrates activity in the neoadjuvant setting [46] and in preclinical studies is effective in
combination with anti-angiogenic treatments [47].
Continued
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Table 1. Continued
Field or treatment Status of research/implications for patient care
Risk assessment and prediction Use of genomic prognostic tests is increasing and has led to altered treatment recommendations in 25%–30% of cases. This
has been associated with an overall decreased use of adjuvant chemotherapy [48]. One prospective non-randomized
cohort study conﬁrmed the prognostic value of the 70-gene signature in terms of 5-year distant recurrence free interval,
and noted an excellent outcome for patients classiﬁed as ‘low risk’ and treated without cytotoxic therapy [49]. ER and
proliferation deﬁne cohorts of patients with early and late recurrence risks. It is noteworthy that ﬁrst-generation tests are
largely calibrated on early recurrence, while the risk of recurrence in luminal disease persists for many years and may be
better addressed by newer assays [50–53].
Following neoadjuvant chemotherapy, assessment of residual tumour burden appears prognostically useful, but validation
and standardization of this as a prognostic marker is just as important as for IHC or molecular assays [54]. Residual
disease after neoadjuvant chemotherapy appears less important in patients with Luminal A or hormone receptor positive,
HER2-positive disease, but pCR seems to be prognostically highly important for non-luminal HER2-positive and triple-
negative disease [55].
Following conventional adjuvant therapy, deﬁnition of residual risk may guide the need for further treatment or clinical
trials. While baseline tumour staging and conventional biological parameters are important, further information may be
obtained from evaluations including genomic signatures and tumour inﬁltrating lymphocytes [56–58].
Immunity and vaccines Therapeutic vaccination remains elusive because of tumour heterogeneity and immune escape mechanisms. Agents, such as
ipilimumab, which suppress regulatory T cells, may tip the immune balance to cause tumour regression [59]. The presence
of tumour-associated lymphocytes in breast cancer is a new independent predictor of response to anthracycline/taxane
neoadjuvant chemotherapy [60]. In node-positive, ER-negative, HER2-negative breast cancer, increasing lymphocytic
inﬁltration is associated with an excellent prognosis [56].
Surgery of the primary Although the risk of local regional relapse is related to the biological aggressiveness of the disease as reﬂected in its intrinsic
subtype, there is no evidence that more extensive surgery will overcome this risk [61]. Effective systemic therapy decreases
loco-regional recurrence [62]. Not all women prefer breast conservation. For those who do, the only absolute
contraindications are positive margins after multiple resections, and the inability to deliver indicated radiotherapy [63, 64].
Surgery of the axilla Substantial new data were presented about the role of and necessity for completion axillary dissection after positive sentinel
nodes for patients with clinically node-negative disease. The IBCSG 23-01 trial found no beneﬁt of axillary dissection in
patients with micrometastatic disease in one or more sentinel lymph nodes [65]. There was increasing acceptance of the
omission of axillary dissection also in patients similar to those included in the ACOSOG Z0011 trial that is with one or
two involved nodes following breast conservation surgery with whole breast radiation therapy [66]. Ongoing studies are
examining the omission of even sentinel node biopsy in patients with ultrasound negative axilla, but this practice remains
experimental [67].
Radiation therapy Clinical trial evidence supports the validity of hypofractionated radiotherapy such as 40 Gy in 15 or 42.5 Gy in 16 fractions in
many patients [68–70]. Such short course whole breast radiation therapy has obvious advantages in terms of patient
convenience and cost.
Trials have demonstrated the safety and efﬁcacy of some forms of partial breast irradiation in selected patients. The main
questions are around the deﬁnition of a suitable group and variability of levels of evidence between several available
intraoperative and postoperative partial breast techniques [71]. ASTRO [72] and ESTRO [73] provide similar guidelines
based on factors such as age, BRCA 1/2, tumour size, margins, ER status, focality, histology, nodal factors, and
neoadjuvant therapy. A number of large randomised clinical trials of partial breast irradiation await formal reporting and
publication of mature outcome data. Partial breast re-irradiation following ‘in breast tumour recurrence’ can be considered
as an alternative to salvage mastectomy in selected cases, although the long-term safety and efﬁcacy of this approach have
not been established [74].
Adjuvant chemotherapy A major unresolved question is the threshold for use of adjuvant cytotoxic chemotherapy for patients with Luminal A or
Luminal B disease. In prospective/retrospective studies, the 21- gene recurrence score (RS) identiﬁes groups who do not
beneﬁt from the addition of chemotherapy in node-negative [75] or node-positive [76] disease. In both these studies based
on randomised trials, chemotherapy beneﬁt was conﬁned to the group with high 21-gene RS. Another series using the 70-
gene signature noted excellent 5-year distant recurrence free interval for the ‘good prognosis’ group without chemotherapy
[49]. PAM50 classiﬁcation showed no beneﬁt of anthracycline-based chemotherapy (CEF) compared with CMF
chemotherapy in patients with either Luminal A or Luminal B disease [77].
For patients with triple-negative disease, optimal chemotherapy regimens have not been deﬁned, but evidence supports the
inclusion of anthracyclines and taxanes, but not bevacizumab, platinums, capecitabine, or gemcitabine [78].
No standard duration of adjuvant chemotherapy has yet been identiﬁed for patients with endocrine non-responsive
disease [79].
Continued
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multi-gene testing remains inaccessible for the majority of
women with early breast cancer. It is for these women that the
Panel believed that the approach adopted by successive St
Gallen Panels based on the available clinico-pathological testing,
and now expressed in the surrogate IHC-based classiﬁcation
shown in Table 2 will be more widely applicable at lesser cost,
notwithstanding its limited validation.
The main reason for attempting distinction between ‘Luminal
A-like’ (more endocrine sensitive, indolent, better prognosis)
and ‘Luminal B-like’ (less endocrine sensitive, more aggressive,
worse prognosis) tumours was recognized to be the differing
implications for the utility or futility of adjuvant cytotoxic
therapy between these groups. Evidence was presented that the
clarity of distinction between ‘Luminal A-like’ and ‘LuminalB-
like’ tumours could be improved by the requirement for
substantial PgR positivity in the deﬁnition of ‘Luminal A-like’
disease [24]. Adding this restriction will have the effect of
reducing the number of patients classiﬁed as ‘Luminal A-like’
and thus increasing the number for whom cytotoxic therapy is
generally recommended. Recognizing that high-quality
pathology and quality assurance programmes are important for
the interpretation of these tests, it was noted that the absolute
values of each IHC parameter/cut-point may vary between
laboratories, and that pending improved standardization local
experience might best deﬁne the locally useful cut-points
between ‘high’ and ‘low’ Ki-67 and PgR.
panel deliberations
The Panel reviewed a series of questions developed by iterative
consultation over the months preceding the conference. Voting
on most questions was in the format yes, no or abstain, where
abstaining was recommended if the Panel member felt a conﬂict
of interest in the question, that there was insufﬁcient evidence to
support an opinion either way or that he or she lacked the
relevant expertise. Detailed voting records for each of the
questions put to the Panel are provided in the supplementary
Appendix S1, available at Annals of Oncology online.
surgery of the primary
The Panel found very few absolute contraindications to breast-
conserving therapy. Margins involved with invasive carcinoma or
DCIS after repeated resection were one such absolute
contraindication. The minimal acceptable surgical margin was felt
to be ‘no ink on invasive tumour’ (i.e. margins free of tumour) by
nearly three quarters of the Panellists and most of the others would
accept a minimum clearance of 1 mm. The Panel was almost
unanimous that breast-conserving surgery should not be carried
out unless postoperative radiation (if indicated, as described below
in the radiation therapy section) could be delivered.
A majority of the Panel considered that relative but not
absolute contraindications to breast-conserving therapy
included very young age (<35 years); extensive or diffuse
Table 1. Continued
Field or treatment Status of research/implications for patient care
Neoadjuvant chemotherapy Because the goals of treatment are the same in terms of ultimate systemic control, the selection of regimen for neoadjuvant
chemotherapy generally follows guidelines similar to those applying to the conventional adjuvant setting [80].
A risk of recurrence (ROR) score based on PAM50 showed that there were no or very few pathological complete responses to
neoadjuvant chemotherapy among patients with low ROR [22]. Other neoadjuvant studies have found that a 70-gene
good prognosis signature and a low 21-gene RS predict low probability of pCR [81, 82].
HER2-targeted therapy Clinical trial results support a standard duration of adjuvant trastuzumab of one year rather than longer [7] or shorter [8]
[83].
Endocrine therapy For premenopausal women with hormone receptor positive breast cancer, the standard endocrine therapy is based on
tamoxifen. Unresolved questions include the necessity for combining ovarian function suppression with tamoxifen, and
the possible substitution of an aromatase inhibitor in combination with ovarian function suppression. The SOFT and
TEXT trials addressing these questions will report results in the near future [46, 84].
Recent evidence from the ATLAS trial suggests that durations of tamoxifen >5 years may be appropriate [9]. In
postmenopausal women with endocrine responsive disease, letrozole therapy administered after 5 years of tamoxifen was
established via the MA.17 study [85]. Recent analyses of this trial suggest that the beneﬁt of letrozole might be even greater
for patients who were premenopausal at the time of initial diagnosis but postmenopausal following completion of ﬁve
years of tamoxifen [86].
Adverse effects of aromatase inhibitors limit their use in a substantial proportion of women, and particular concern may exist
for those with pre-existing ischaemic cardiovascular disease [87, 88].
Young women Women under 40 years of age have relatively higher incidence of triple-negative and HER2-positive disease [89]. One study
suggests that very young women, aged ≤35, with triple-negative disease may have particularly high likelihood of achieving
pCR with neoadjuvant chemotherapy [90].
Social issues such as fertility, sexual functioning, and the care of young children may be particularly important for younger
women [91].
Follow-up of survivors A number of studies have failed to show beneﬁt from more, compared with less intensive follow-up investigations. In at least
some health care delivery settings, follow-up conducted by oncology nurses is feasible and might be a reasonable
alternative to specialist clinical surveillance [92].
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microcalciﬁcations where the presence of malignancy cannot be
reliably excluded without complete excision; multicentric
disease; tumour location near the nipple and mutations of the
BRCA1 or BRCA2 genes. Substantial minority support added
multifocal disease, extensive vascular invasion and an extensive
intraductal component to this list of relative contraindications.
Positive family history and unfavourable biology based on
genomic proﬁling were not considered to be contraindications
to breast-conserving therapy.
Nipple-sparing surgery was considered acceptable, provided
the margin close to the nipple was not involved. The vast
majority of Panel members thought magnetic resonance
imaging should not be routinely used in the assessment of
newly diagnosed breast cancer.
surgery of the axilla
The Panel believed that axillary dissection could be safely
omitted in patients with one or two positive sentinel nodes
following breast-conserving surgery when whole breast
radiation therapy is planned. The Panel was nearly equally
divided whether this recommendation also applied to
mastectomy followed by radiotherapy, but was almost
unanimous in the need for axillary dissection if no radiotherapy
was planned.
The Panel also considered that axillary dissection was
required with three or more involved sentinel nodes or if nodes
were clinically involved before surgery and conﬁrmed by biopsy.
radiation therapy
The Panel strongly agreed that ‘short course’ radiotherapy, such
as 40 Gy in 15 or 42.5 Gy in 16 fractions, could be offered as a
standard for at least some patients, with a slim majority
thinking that this would be suitable for almost all patients. The
Panel agreed that short course radiotherapy was an option
whether or not a boost to the tumour bed was planned. A large
majority of Panel members thought that there were deﬁnable
Table 2. Surrogate deﬁnitions of intrinsic subtypes of breast cancer
Intrinsic subtype Clinico-pathologic surrogate deﬁnition Notes
Luminal A ‘Luminal A-like’
all of:
ER and PgR positive
HER2 negative
Ki-67 ‘low’a
Recurrence risk ‘low’ based on
multi-gene-expression assay (if available)b
The cut-point between ‘high’ and ‘low’ values for Ki-67 varies between
laboratories.a A level of <14% best correlated with the gene-expression
deﬁnition of Luminal A based on the results in a single reference
laboratory [23]. Similarly, the added value of PgR in distinguishing
between ‘Luminal A-like’ and ‘Luminal B-like’ subtypes derives from the
work of Prat et al. which used a PgR cut-point of ≥20% to best
correspond to Luminal A subtype [24]. Quality assurance programmes
are essential for laboratories reporting these results.
Luminal B ‘Luminal B-like (HER2 negative)’
ER positive
HER2 negative
and at least one of:
Ki-67 ‘high’
PgR ‘negative or low’
Recurrence risk ‘high’ based on
multi-gene-expression assay (if available)b
‘Luminal B-like’ disease comprises those luminal cases which lack the
characteristics noted above for ‘Luminal A-like’ disease. Thus, either a
high Ki-67a value or a low PgR value (see above) may be used to
distinguish between ‘Luminal A-like’ and ‘Luminal B-like (HER2
negative)’.
‘Luminal B-like (HER2 positive)’
ER positive
HER2 over-expressed or ampliﬁed
Any Ki-67
Any PgR
Erb-B2 overexpression ‘HER2 positive (non-luminal)’
HER2 over-expressed or ampliﬁed
ER and PgR absent
‘Basal-like’ ‘Triple negative (ductal)’
ER and PgR absent
HER2 negative
There is an 80% overlap between ‘triple-negative’ and intrinsic ‘basal-like’
subtype. Some cases with low-positive ER staining may cluster with non-
luminal subtypes on gene-expression analysis. ‘Triple negative’ also
includes some special histological types such as adenoid cystic
carcinoma.
aA majority of the Panel voted that a threshold of ≥20% was indicative of ‘high’ Ki-67 status. Others, concerned about the high degree of inter-laboratory
variation in Ki-67 measurement [26] and the possibility for undertreatment of patients with luminal disease who might beneﬁt from chemotherapy, would use
a lower (local laboratory speciﬁc) cut-point to deﬁne Ki-67 ‘high’ or use multi-gene-expression assay results, if available.
bThis factor was added during Panel deliberations after circulation of the ﬁrst draft of the manuscript, to reﬂect a strong minority view. Although neither the
21-gene RS nor the 70-gene signature was designed to deﬁne intrinsic subtypes, a concordance study noted that over 90% of cases with a low RS and almost
80% of those with a 70-gene low-risk signature were classiﬁed as Luminal A [95].
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groups of patients not requiring radiotherapy following breast-
conserving surgery, and that these might include the elderly and
those with substantial comorbidity. The Panel could not reach a
majority view regarding the current acceptability of the various
techniques for partial breast radiation as deﬁnitive treatment.
Post-mastectomy radiotherapy was considered indicated by
almost all Panel members for patients with four or more
positive nodes, while the majority would not advise post-
mastectomy irradiation for those with one to three positive
nodes, except in the presence of adverse tumour pathology. The
Panel was content to omit post-mastectomy radiotherapy with
pathologic uninvolved nodes even when fewer than eight nodes
had been examined and if the tumour was ≤5 cm. Two-thirds
felt that radiation therapy should be given after mastectomy if
positive sentinel nodes were not followed by axillary dissection.
Other indications recommended by the Panel for post-
mastectomy radiotherapy included positive deep margins and,
for two-thirds of the Panel, tumours greater than 5 cm
regardless of the nodal status. However, the Panel strongly
rejected needing radiotherapy solely based on Grade 3,
lymphovascular invasion, HER2-positive status or triple-
negative disease.
Areas to be irradiated following mastectomy and axillary
dissection should not be inﬂuenced by any neoadjuvant
systemic therapy or by the intrinsic subtype of the tumour.
There was no clear agreement about the necessity to include the
supraclavicular fossa, though trials have routinely included this
area. Most Panel members would not include the internal
mammary nodes and a strong majority felt that the axilla
should not be radiated after dissection.
pathology
The Panel recognized substantial progress in the pathological
characterization of tumour subtypes. There was little change in
the classiﬁcation of HER2-positive or triple-negative disease.
The majority of the Panel accepted that a useful surrogate
deﬁnition of Luminal A-like as distinct from Luminal B-like
disease could be made using a combination of ER, PgR and
Ki-67, without requiring molecular diagnostics. Ki-67 has been
used for more than two decades as a prognostic marker in early
breast cancer [110–118]. The Panel did not accept that
distinction between Luminal A-like and Luminal B-like
tumours could be made with ER and PgR alone, and a clear
majority voted that grade 3 could not be used as a substitute for
high Ki-67 for this purpose. The Panel noted that standardized
cut-offs for Ki-67 have not been established and laboratory
speciﬁc values should be used, but the majority of the Panel
voted that a threshold of ≥20% was clearly indicative of ‘high’
Ki-67 status. A minority questioned the role of Ki-67 in breast
Table 3. Systemic treatment recommendations
‘Subtype’ Type of therapy Notes on therapy
‘Luminal A-like’ Endocrine therapy is the most critical
intervention and is often used alone.
Cytotoxics may be added in selected patients. Relative indications
for the addition of cytotoxics accepted by a majority of the Panel
included:
(i) high 21-gene RS (i.e. >25), if available;
(ii) 70-gene high risk status, if available;
(iii) grade 3 disease;
(iv) involvement of four or more lymph nodes (a minority required
only one node).
The Panel was almost equally divided as to whether young age
(<35 years) per se was an indication to add cytotoxics.
Studies suggest a wide geographical divergence in the threshold
indications for the inclusion of cytotoxics for the treatment of
patients with luminal disease [96].
‘Luminal B-like (HER2 negative)’ Endocrine therapy for all patients, cytotoxic
therapy for most.
‘Luminal B-like (HER2 positive)’ Cytotoxics + anti-HER2 + endocrine therapy No data are available to support the omission of cytotoxics in this
group.
‘HER2 positive (non-luminal)’ Cytotoxics + anti-HER2 Threshold for use of anti-HER2 therapy was deﬁned as pT1b or
larger tumour or node-positivity.
‘Triple negative (ductal)’ Cytotoxics
‘Special histological types’a
A. Endocrine responsive Endocrine therapy
B. Endocrine non-responsive Cytotoxics Adenoid cystic carcinomas may not require any adjuvant cytotoxics
(if node negative).
aSpecial histological types: endocrine responsive (cribriform, tubular and mucinous); endocrine non-responsive (apocrine, medullary, adenoid cystic and
metaplastic).
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cancer treatment decisions. The Panel stressed the need for
standardization, and that laboratories should participate in
quality assurance programmes.
The Panel was strongly of the opinion that intrinsic subtypes,
including those deﬁned by the clinico-pathological surrogates,
should inﬂuence whether or not chemotherapy was used, but
not the choice of the cytotoxic regimen. After clinico-
pathological assessment, a slim majority of the Panel was in
favour of requesting a multi-gene assay in node-negative, ER-
positive and HER2-negative cases. The Panel considered that
only the 21-gene RS was predictive of chemotherapy
responsiveness, though a substantial minority would also
endorse PAM50 or the 70-gene signature for this purpose. This
led to a recommendation that selection of patients who might
forego chemotherapy could be based on the 21-gene RS, but the
Panel did not offer majority endorsement for PAM50, the 70-
gene signature or EPClin as yet established for this purpose.
For patients with ER-positive, HER2-negative disease, the use
of molecular diagnostics was felt to be unnecessary in low-risk
patients such as those with a tumour size of ≤1 cm in the setting
of negative lymph nodes, since chemotherapy would be unlikely
to be given anyway. Similarly, patients with a higher risk such as
those with a tumour size >5 cm, inﬂammatory breast cancer,
those with four or more involved nodes, or a very low ER
positivity (e.g. 5%) might not beneﬁt from molecular
diagnostics because chemotherapy would be likely to be offered
in any case. Patients in whom chemotherapy was thought to be
of uncertain indication and who might, therefore, beneﬁt from
molecular diagnostics were felt to include selected patients with
node-negative disease, those with one to three positive nodes,
and patients aged <35.
In the determination of HER2 status for treatment purposes,
the Panel did not believe that polysomy of chromosome 17, or
heterogeneity of expression of HER2 need to be considered.
adjuvant endocrine therapy in premenopausal
women
The large majority of the Panel said that tamoxifen alone was
the default adjuvant endocrine therapy for premenopausal
patients. In light of recent trial evidence, it was felt that at least
some patients should have a treatment duration of 10 years,
although this may not be needed by all patients. Most Panellists
thought ovarian suppression need not be added to tamoxifen,
but Panellists were evenly divided for patients <40 years of age.
Most of the Panel regarded both ovarian suppression alone
without tamoxifen and its combination with aromatase
inhibitors as inappropriate unless tamoxifen was
contraindicated.
adjuvant endocrine therapy in postmenopausal
women
The Panel strongly believed that some postmenopausal women
could be treated with tamoxifen alone. If an aromatase inhibitor
were included in the regimen, Panellists were equally divided
whether treatment should start with the aromatase inhibitor,
although this strategy was strongly preferred for patients at high
risk. Most Panellists believed that initial aromatase inhibitor
therapy could be replaced by tamoxifen after 2 years, if there
were a reason to do so. Extension of aromatase inhibitor therapy
beyond the ﬁrst ﬁve years for patients with node-positive, but
not node-negative disease was strongly supported, for patients
whose initial treatment was tamoxifen or whose initial therapy
was <5 years of an aromatase inhibitor. The Panel was equally
divided concerning an extended duration of aromatase inhibitor
therapy beyond 5 years of treatment with these agents. Extended
adjuvant endocrine therapy using tamoxifen is a consideration
after a 5-year course of an aromatase inhibitor, though this
approach has not been directly studied.
adjuvant cytotoxic chemotherapy
The Panel was clearly of the opinion that factors arguing for the
inclusion of chemotherapy were histological grade 3 tumours,
high Ki-67, low hormone receptor status, HER2 positivity or
triple-negative status, high 21-gene RS, high-risk 70-gene
signature and the involvement of more than three lymph nodes.
Most felt that nodal positivity per se was not an indication for
chemotherapy but very few would forego chemotherapy for
patients with four or more positive nodes. Lymphovascular
invasion was not recognized as an indication, while the Panel
was equally divided whether young age (<35 years) was an
indication.
The Panel was of the strong opinion that patients with
Luminal A-like disease were ‘less responsive to chemotherapy’,
but this treatment could be added to endocrine therapy based
on the large tumour volume, assessment of risk or patient
preference. The Panel did not select a speciﬁc chemotherapy
regimen for these patients and expressed the view that any of
the standard regimens, including the ﬁrst- and second-
generation regimens (CMF, AC, TC), could be considered.
For patients with Luminal B (HER2-negative) disease, the
majority of the Panel considered chemotherapy to be indicated.
Chemotherapy regimens for Luminal B (HER2-negative)
disease should generally contain anthracyclines and (by a slim
majority) taxanes. Half the Panel agreed that such
chemotherapy should be delivered for at least six cycles, but the
Panel did not endorse the exclusive use of a dose dense regimen.
For patients with HER2-positive disease, the Panel strongly
believed, while there was no speciﬁcally preferred regimen,
chemotherapy should include a taxane and, for most Panel
members, also an anthracycline.
For patients with ‘basal-like’ (triple-negative ductal) disease,
the Panel strongly endorsed both anthracyclines and taxanes,
and did not believe that platinum, or regimens emphasizing
alkylating agents were speciﬁcally required. There was no clear
consensus on the role of dose dense regimens, though a
substantial minority expressed support for such treatment.
General considerations inﬂuencing the choice of
chemotherapy regimen were thought to include a desire to
preserve fertility, the avoidance of alopecia and the presence of
co-morbidities, but not intrinsic subtype or the presence of
BRCA1 or BRCA2mutation. Older chronological age should not
necessarily inﬂuence the choice of regimen [119], but
assessment of co-morbidities and general health was considered,
especially important in older patients.
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anti-HER2 therapies
For patients whose tumours show ampliﬁcation or
overexpression of HER2, the Panel considered that trastuzumab
therapy was indicated for patients with tumours >5 mm, while
some Panellists would treat patients with such tumours of any
size. Most felt that trastuzumab should be given concurrently
with a taxane, but not with an anthracycline. The Panel was
prepared to endorse trastuzumab (with endocrine therapy, if
indicated) without chemotherapy only if chemotherapy were
contraindicated. The Panel was unanimous that the duration of
trastuzumab should be 1 year.
neoadjuvant cytotoxic chemotherapy
The Panel was split about whether neoadjuvant chemotherapy
had beneﬁts beyond local downstaging. The Panel did not
support additional postoperative adjuvant chemotherapy
following a full course of neoadjuvant chemotherapy, whether
or not pCR were achieved. Most believe when neoadjuvant
therapy is given outside of a clinical trial, the full course of
chemotherapy should be completed before surgery. In the
unusual situation in which a surgery is carried out after less
than a full course of neoadjuvant chemotherapy most Panel
members would complete the course postoperatively.
neoadjuvant anti-HER2 therapy
For patients with HER2-positive disease, the Panel was strongly
of the opinion that neoadjuvant treatment should include anti-
HER2 drugs, and the majority recommended the use of
chemotherapy plus trastuzumab alone (without additional anti-
HER agents).
neoadjuvant endocrine therapy
The Panel strongly endorsed endocrine therapy alone as
neoadjuvant treatment for postmenopausal patients with
strongly positive hormone receptors and low proliferating
disease, and most thought that such treatment should be
continued until maximal response.
bisphosphonates
The Panel considered several situations in which
bisphosphonates might be used with the aim of improving
disease-free survival, but did not endorse such treatment for this
purpose in any group, though a substantial minority felt that
premenopausal patients receiving an LHRH agonist plus
tamoxifen or clearly postmenopausal patients might derive
beneﬁt from such treatment. Denosumab was not endorsed for
adjuvant use.
follow-up
The majority of the Panel believed that regular follow-up after
the completion of immediate treatment (excluding long-term
endocrine therapy) was appropriate, but that this could be
supervised by a nurse specialist, rather than a surgeon or
oncologist. The majority of the Panel also believed that follow-
up should be done in person and not by telephone.
summary of treatment recommendations
The conference endorsed recent trial evidence supporting less
extensive local therapies. It reﬁned and re-iterated the value of
clinico-pathological surrogate deﬁnitions resembling intrinsic
subtypes to guide selection of systemic adjuvant therapies. The
Panel recognized the superior accuracy and reproducibility of
multi-gene molecular assays, but recognized that these assays
are not available in all parts of the world. The Panel also noted
the variability in the current levels of evidence to support the
use of the individual multi-gene assays. Ongoing trials will
prospectively deﬁne the value of chemotherapy in addition to
endocrine therapy in patients with luminal disease in the node-
negative (TAILORx, MINDACT) and node-positive
(MINDACT, RxPONDER) cohorts. It is therefore to be hoped
that a future St Gallen Consensus conference will be able to
provide more robustly supported recommendations for
treatment of such patients.
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